Serimmune is an innovative company specializing in immune intelligence, particularly through its Serum Epitope Repertoire Analysis (SERA) platform. This proprietary technology utilizes bacterial display peptide libraries and next-generation sequencing to conduct comprehensive profiling of antibody repertoires. By identifying disease-specific epitopes across a wide range of proteins, SERA enables researchers to gain insights into the immune responses associated with various diseases, including infectious diseases, autoimmune disorders, and cancer. The platform's ability to perform unlimited multiplexing allows for simultaneous analysis of multiple pathogens from a single specimen, making it a powerful tool for both research and clinical applications.

In addition to its broad applications in biomarker discovery and disease stratification, Serimmune's SERA platform employs advanced bioinformatics methods to enhance the precision of epitope mapping. This includes the identification of both validated and novel antigens, which can aid in the development of targeted therapies and vaccines. The platform has demonstrated its utility in various contexts, such as tracking immune responses in oncology and monitoring seropositivity for infectious diseases like COVID-19 and Lyme disease. Overall, Serimmune's technologies are positioned to significantly advance the understanding of immune responses and improve diagnostic and therapeutic strategies across multiple health domains.

United States

Serimmune is an immune intelligence company that provides a holistic view of immunity to identify environmental factors in disease and health. Serimmune’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity.

Serimmune

Company Details